Association of clinical features with HER-2/Neu

Top PDF Association of clinical features with HER-2/Neu:

Original Article Association between hormone receptors and HER-2/neu is age-related

Original Article Association between hormone receptors and HER-2/neu is age-related

Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China Received May 16, 2015; Accepted June 26, 2015; Epub July 1, 2015; Published July 15, 2015 Abstract: Purpose: To investigate the association between hormone receptors and HER-2/neu in different age groups of women with breast cancers. Methods: A total of 1036 women with breast cancers were recruited. All the patients were divided into nine groups. The expression of hormone receptors and HER-2/neu was studied by IHC, while FISH test was used to determine HER-2/neu status in cases scored IHC 2+. The association between hormone receptors and HER-2/neu in different age groups was evaluated using the χ 2 test. Multivariate analysis was used to find out the independent factors predicting HER-2/neu amplification. Significant findings: The expression of ER and PR was inversely correlated with HER-2/neu status in women aged >40 years. By multivariate analysis, as far as the overall groups were concerned, PR, lymph node status and tumor grade were independently associated with HER-2/
Show more

8 Read more

Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia

Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia

An inverse association between ER and PR with HER-2/ neu has been observed by others [10, 13, 14]. In our study, ER negativity was more strongly associated with HER-2/neu negativity. It was the same with PR negativity. However our study has some limitations. Malaysian population represent a multiracial community with Chinese, Malays and Indians as major racial groups and this biological diversity may be responsible for differences in ER, PR and HER-2/neu expression. Furthermore our results may have been affected by the use of immuno histochemistry analysis of HER-2/neu. Therefore more studies are needed from Malaysia to verify our findings.
Show more

5 Read more

Antibody association with HER 2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc mediated activation of DCs

Antibody association with HER 2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc mediated activation of DCs

It is interesting to note that the CD8 + T cell activation and pro- liferation measured in the spleen was higher than expected when the intact 7.16.4 mAb was given with vaccine, even though the in vivo imaging studies demonstrated localization in the VDLN with minimal uptake in the spleen. This observation could be due to the endogenous neu in our transgenic model, but the relatively low background level from the intact 7.16.4 mAb + control vac- cine treatment would suggest otherwise. Although DC activity mainly takes place in the draining lymph node, systemic distri- bution of DCs that carry locally administered antigens has been observed under certain conditions (40–42). In our DEAD assay experiments, CD11c + DCs in the spleen proliferated naive clono- typic CD8 + T cells just as well as those in VDLNs. Furthermore, the intact 7.16.4 mAb + neu-targeted vaccine treatment enhanced the cross-priming capabilities of splenic CD8 + and CD8 – DCs. We believe that DCs in a systemic GM-CSF milieu, created by the neu- targeted vaccine, are capable of migrating from the vaccine site to other organs such as the spleen, hence leading to the ampli- fication of T cell functions at those sites. Additional studies are needed to elucidate the migratory pattern of DCs in a GM-CSF circulatory environment, starting with the in vivo imaging of vac- cinated mice beyond the 48-hour time period.
Show more

13 Read more

HER-2/Neu over-expression in invasive Bladder Cancer in Sudanese Patients

HER-2/Neu over-expression in invasive Bladder Cancer in Sudanese Patients

Previous studies on HER-2 expression in bladder carcinoma using Western blot analysis and IHC have found a correlation between increased HER-2 expression and both higher tumor stage and grade ( 20,21).but our study contradicted these studies, we found no significant correlation between HER-2 over-expression and histological subtype of bladder cancer (TCC, SCC) (p=0.55), and also no significant correlation between HER-2 over expression and tumors grade (P=0.06). Others (16, 19, 22) have reported a significant association between HER-2 over-expression and a higher tumor grade. Thus, shawky et al. ( 23) studied HER-2 over-expression in invasive bladder carcinoma among cohort patients. HER-2 over-expression was associated with high-grade bladder cancers. Similarly, in a recent study ( 24) on 59 patients, HER-2 over-expression was significantly correlated with the differentiation grade, our study contradicted for these studies;
Show more

10 Read more

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Yes 20 (14.7) 35 (6.6) Notes: a Adjusted for age, type of surgery, tumor size, endovascular or lymphatic tumor emboli, status of resection margin, triple-negative (Tn) breast cancer, B-cell lymphoma 2, and Ki-6. b Based on Pearson’s χ 2 test (using Fisher’s exact test if n # 5). The number of studies included in the meta-analysis with different treatment endpoints was too small to perform a meaningful analysis of its predictive role. However, there is an emerging consensus that Bcl2 plays a key role in deter- mining response to endocrine therapy and chemotherapy. 21 Bcl2 is an estrogen-responsive gene, and many clinical studies have shown an association with a favorable response to endocrine therapy. 21 Bcl2 is a component of the 21-gene signature used to predict recurrence in tamoxifen-treated ER-positive, node-negative breast cancer. Its role is being evaluated prospectively in the TAILORx (Trial Assigning Individualized Options for Treatment (Rx)) trial. 22
Show more

11 Read more

HER-2/neu overexpression correlates with increased expression of VEGF in primary breast carcinoma

HER-2/neu overexpression correlates with increased expression of VEGF in primary breast carcinoma

Association of HER-2/neu and VEGF with different histological parameters: Before analyzing the possible association between HER-2/neu and VEGF we tried to find out any association of these two markers with different histological characteristics. HER-2/neu overexpression was associated with histologic grade but not with tumor size and lymph node involvement, while VEGF expression was not associated with any of the parameters (Table-2). HER-2/neu overexpression was observed in 50%, 75.80% and 20.70% cases among histologic grades I, II and III respectively. This indicated higher expression of HER-2/neu in grade II followed by grade I and least in grade III. This finding of lower HER-2/neu positivity in the worst histologic grade is unusual.
Show more

8 Read more

A study on role of HER 2/NEU over expression in gastric carcinoma in south Indian population

A study on role of HER 2/NEU over expression in gastric carcinoma in south Indian population

DISCUSSION Sex difference with male preponderance is correlating with others studies owing to risk factors such as smoking and drinkind are common among males. Gastric adeno carcinoma even thogh it is a disease of the 6 th and seventh decade , occurred at even young age of 20 years. A.Ieni and his colleagues studied the incidence of her2/neu in gastric carcinoma patients. The mean age in their study 68.3 years and the youngest incidence was 41 years{A.IENI, 2013 #2}. But our study reveals the mean age to be a decade less than Sicilian study. Antral carcinomas are common which could be explained by association with H.pylori infection.
Show more

101 Read more

Expression and prognostic significance of E Cadherin, EGFR,    p53 and HER-2/NEU in Gastric Carcinoma.

Expression and prognostic significance of E Cadherin, EGFR, p53 and HER-2/NEU in Gastric Carcinoma.

.The protein encoded by this gene is suggested to be a growth factor receptor involved in the growth and progression of malignant cells (10) . Despite many studies that have been conducted in gastric carcinoma worldwide for the expression of E Cadherin, EGFR, p53 and HER-2/Neu and for their prognostic importance, the results are still contradictory. Some found a statistically significant association of these markers with prognosis and survival, while others found no such association. In a related development, targeted therapy against EGFR and HER-2/Neu has attracted much attention recently. Hence accurate evaluation of expression of EGFR and HER-2/Neu proteins might help to identify eligible candidates for new targeted therapy.
Show more

166 Read more

Cytoplasmic p21WAF1/CIP1 expression is correlated with HER 2/ neu in breast cancer and is an independent predictor of prognosis

Cytoplasmic p21WAF1/CIP1 expression is correlated with HER 2/ neu in breast cancer and is an independent predictor of prognosis

between the HER-2 breast tumours and nuclear p21 WAF1/CIP1 further implies the ability of HER-2 to mislo- calise p21 WAF1/CIP1 . Nuclear p21 WAF1/CIP1 is required to preferentially inhibit cyclin/CDK complexes to ensure DNA repair and growth suppression of transformed cells. This process is determined by a carboxyterminal nuclear locali- sation signal, while mechanisms underlying nuclear export of p21 WAF1/CIP1 remain to be determined. In vitro, active phosphorylated Akt binds p21 WAF1/CIP1 and phosphory- lates threonine 145 in the nuclear localisation signal to produce cytoplasmic p21 WAF1/CIP1 [21]. In a preliminary series of five breast cancers, immunohistochemical detec- tion of phosphorylated Akt was associated with p21 WAF1/CIP1 in both the nucleus and the cytoplasm, sug- gesting an association with HER-2 activation [21]. This implies that the relationship between HER-2 and the sub- cellular localisation of p21 WAF1/CIP1 is not exclusive in vitro and in vivo, but reflects a preferential cytoplasmic localisa- tion of p21 WAF1/CIP1 .
Show more

8 Read more

Prevalence of HER-2/ neu receptor amplification and its effects over prognosis of the patients with breast cancer

Prevalence of HER-2/ neu receptor amplification and its effects over prognosis of the patients with breast cancer

DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20201905 ABSTRACT Background: The diagnosis and prognosis of patients with breast cancer is routinely carried out with biopsy of growth by H&E staining but it is not commonly practice with various immunomarkers including HER2/neu. However HER2/neu association in breast tumour patients with prognosis has not been studied much, so this study is aim to evaluate the frequency of HER2 (human epidermal growth factor receptor) amplification and its effects over prognosis among the patients with breast cancer.
Show more

5 Read more

Role of microvessel density, HER-2/ NEU expression and CD-34 in prognostication and grading of bladder carcinomas.

Role of microvessel density, HER-2/ NEU expression and CD-34 in prognostication and grading of bladder carcinomas.

Sarcomatoid variants are a group of biphasic malignant neoplasms exhibiting morphologic evidence of both epithelial and mesenchymal differentiation. More than 100 cases have been reported since the mid 1800s, many originally classified as carcinosarcoma, but in general this is a rare tumour. (69,70) The significance of diagnosing this lesion lies in its association with a poor prognosis. These tumours are typically diagnosed at advanced local stage, and they often exhibit nodal or distant metastases. 70% of patients will die within 2 years of diagnosis.
Show more

140 Read more

Immunohistochemical expression of markers KI67 and HER 2 NEU and its correlation with clinicopathological parameters in urothelial tumors

Immunohistochemical expression of markers KI67 and HER 2 NEU and its correlation with clinicopathological parameters in urothelial tumors

In our study co-expression of both markers varied with clinical parameters and histopathological parameters. Significant association with tumor histopathological parameters was observed. Co-expression of both markers was demonstrated in 25 % of low grade, 40 % of intermediate grade and 78.8% of high grade. In muscle invasive tumors 70.6% showed co- expression as compared to non muscle invasive tumors (30.4%). Co-expression of both markers correlated well with tumor grade and muscle invasion. Evaluation of both the markers expression was more accurate in predicting aggression and progression of the tumor. Thus, Ki67 and Her2neu co- expression was a superior to single marker expression in predicting tumor prognosis. We had 3 each cases of recurrence and death on follow up 1 year which had high co-expression of both the markers. Our study failed to identify a significant difference in survival in tumors with or without both markers (Ki67&Her2neu) over expression. This limitation may be due to our shorter study duration and small sample size. Larger cohort studies may be necessary to obtain a significant correlation in the above mentioned variables.
Show more

5 Read more

HER 2 therapy  HER 2/neu diagnostics in breast cancer

HER 2 therapy HER 2/neu diagnostics in breast cancer

The HER-2/neu test cleared by the FDA is intended to measure HER-2/neu ECD quantitatively in serum of women with MBC. The use of the HER-2/neu test is indicated for follow up and monitoring of patients with MBC whose initial serum HER-2/neu value is above 15 ng/ml. HER-2/neu values should be used in conjunction with information available from clinical and other diagnostic procedures in the management of MBC. The clinical utility of the serum measurement of HER-2/neu as a prognostic indicator for early recurrence and in the management of patients on immunotherapy regimens has not been fully established. A patient has an elevated serum HER-2/neu level if it is above 15 ng/ml. The upper limit of normal, defined as the lowest concentration that exceeds 95% of the values for normal healthy premenopausal and postmenopausal women, was determined as part of the data submitted to the FDA. The patient population included 121 serum samples from healthy premenopausal women and a total of 120 serum samples drawn from healthy postmenopausal women. In the population of 241 healthy women, 95% of the serum HER-2/
Show more

11 Read more

Immunization with a HER 2/neu helper peptide vaccine generates HER 2/neu CD8 T cell immunity in cancer patients

Immunization with a HER 2/neu helper peptide vaccine generates HER 2/neu CD8 T cell immunity in cancer patients

Discussion The cytolytic T-cell response is believed to be the critical immune effector arm in mediating potential antitumor immunity. Thus, studies of tumor immunity primarily have focused on the identification of MHC class I epi- topes for tumor-associated antigens such as MAGE-1 (30), NY-ESO-1 (31), HER-2/neu (6, 7), tyrosinase (32), and gp-100 (33). In in vitro experiments, these epitopes, when presented in the context of MHC class I, activate CD8 T cells that can directly lyse tumors. Therefore, sev- eral clinical trials have been conducted assessing the fea- sibility and efficacy of cancer vaccination with peptide- Figure 2
Show more

9 Read more

Evaluation of HER-2/neu status in Gastric Carcinoma

Evaluation of HER-2/neu status in Gastric Carcinoma

only in 6% of patients with no difference between the trastuzumab plus chemotherapy and chemotherapy alone groups. Establishing the HER-2/neu status in advanced gastric cancers and in OG junction cancers has become a routine diagnostic histopathological investigation. After TOGA trial combination of Trastuzumab with Cisplatin and 5FU doublet is now a standard treatment options for gastric carcinoma patients with HER-2/neu positivity.. FDA has approved Trastuzumab use in patients with Her-2/neu positive carcinoma stomach patients. In addition to Herceptin, Lapatinib is also being investigated in patients with HER-2/neu positive gastric cancer. LOGIC, a phase III clinical trial in which Lapatinib is being used along with Oxaliplatin and Capecitabine is ongoing. sIn a Phase II trial it showed a median survival of 5 months with an overall response rate of 9%. The TYTAN trial is an ongoing trial evaluating Lapatinib with Paclitaxel in second line setting.
Show more

106 Read more

Analysis in Carcinoma Stomach Her-2/neu Positivity by Immuno-histochemistry

Analysis in Carcinoma Stomach Her-2/neu Positivity by Immuno-histochemistry

of c-erbB-2 has been demonstrated in a small subset of gastric cancers and overexpression observed correlates with worst prognosis. The expression of angiogenesis factors such as vascular endothelial growth factor has been observed in a subset of gastric cancers, indicating the potential role of angiogenesis inhibitor therapy. Membrane-type matrix metalloproteinase is preferentially expressed in some gastric cancer cells with co-localization and activation of the zymogens proMMP-2. Advanced gastric cancer patients express increased activation of plasminogen. Specific alterations such as these need true prevalence determination and further characterization in gastric cancer before genetic tests can be designed for clinical use.
Show more

122 Read more

Cancer biomarker HER-2/neu in breast cancer in Indian women

Cancer biomarker HER-2/neu in breast cancer in Indian women

neu protein, such as the tyrosine kinase inhibitor lapatinib, which appears to have clinical activity after failure of tras- tuzumab therapy. 24 Tumors, including metastatic lesions, shed large numbers of tumor cells into the blood circulation, and the presence of circulating tumor cells is of biologic relevance in the metastatic setting. Based on the hypothesis that the pheno- type of circulating tumor cells may reflect the phenotype of metastatic disease, characterization of circulating tumor cells may be useful for reassessment of HER-2/neu status and additional therapeutic cancer biomarkers. However, this option is limited to those patients with detectable circulating tumor cells. Reported positivity rates for circulating tumor cells in metastatic breast cancer patients range from 20%
Show more

6 Read more

Effects of ectopic HER-2/neu gene expression on the COX-2/PGE2/P450arom signaling pathway in endometrial carcinoma cells: HER-2/neu gene expression in endometrial carcinoma cells

Effects of ectopic HER-2/neu gene expression on the COX-2/PGE2/P450arom signaling pathway in endometrial carcinoma cells: HER-2/neu gene expression in endometrial carcinoma cells

An important member of the epidermal growth factor re- ceptor (EGFR) family, the proto-oncogene HER-2/neu en- codes a 185-kD transmembrane glycoprotein with tyrosine kinase activity [5]. HER-2/neu over-expression typically oc- curs in the placenta, embryonic epithelial tissue, and several types of tumor cells. In contrast, HER-2/neu is absent or minimally expressed in normal tissues [6]. The positive ex- pression rate of the HER-2/neu protein in endometrial car- cinoma is associated with clinical staging, a lower degree of tissue differentiation, and lymph node metastasis [7]. We have applied RT-PCR and ELISA to detect the expression of HER-2/neu, COX-2, p450arom and PGE2 in normal endometrium, hyperplasia endometrium and endometrial carcinoma respectively. The results showed that the expres- sion of HER-2/neu was significantly correlated with patho- logic grading, FIGO staging, and lymph node metastasis. But it has no correlation with menopausal status [8]. There are some studies also shows that the HER-2/neu gene con- tributes to the progression of carcinomas and tumor resist- ance to chemotherapy [9-11]. A better characterization of this proto-oncogene can lend insight to the pathogenesis and molecular mechanisms involved in the development of endometrial carcinoma.
Show more

6 Read more

HER 2 neu Expression in Colorectal Adenocarcinoma and Its Correlation with Clinicopathologic Variables

HER 2 neu Expression in Colorectal Adenocarcinoma and Its Correlation with Clinicopathologic Variables

82 DISCUSSION Colorectal cancer is one of the most common leading causes of cancer related mortality and account for approximately 9% of all human cancers. Eventhough the tumour is diagnosed by histopathology and tumour grade and stage are strong prognostic factors, identification of newer prognostic indicators such as expression of various immunological markers arises depending on which clinical behaviour and treatment differs. Various literature have shown that detection of HER-2/neu is a useful marker and is used to predict the outcome of colorectal cancers.
Show more

140 Read more

HER-2/neu and E-cadherin Expression and Microsatellite Instability in Gastric Dysplasia

HER-2/neu and E-cadherin Expression and Microsatellite Instability in Gastric Dysplasia

Both cytoplasmic and membranous HER-2/ neu proteins were confirmed to be a 185-kDa whole molecule by immunoblotting. 21 Garcia et al. showed that cytosolic HER-2 level of gastric carcinoma cells was associated with an unfavorable outcome. 32 It has been suggested that because proteins are synthesized in the ribosomes, the antibody may detect cytoplasmic precursors of the final product. 33 As with breast cancer, it has been observed that only cases with membrane reactivity are linked to HER- 2 gene amplification and clinical response to Herceptin therapy. 34
Show more

8 Read more

Show all 10000 documents...